Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Teva pharmaceutical industries ltd symbols : Regn save search
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
Published: 2023-05-19 (Crawled : 09:00) - globenewswire.com
ALVO | $13.54 1.05% 0.74% 190K
|
n/a
|
| O: 8.94%
H: 0.0%
C: -7.65%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.36%
H: 1.01%
C: 0.82%
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: 0.29%
H: 1.35%
C: 0.87%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: 0.64%
H: 1.56%
C: 0.9%
KMDA | $5.18 1.57% 1.16% 11K
|
Health Technology
|
| O: 2.31%
H: 1.86%
C: -0.2%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: 0.09%
H: 0.64%
C: -0.45%
business update financial results
EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review
Published: 2022-10-12 (Crawled : 13:00) - biospace.com/
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: 0.0%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: 0.15%
H: 1.25%
C: -1.42%
eylea treatment fda review injection
Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO
Published: 2022-09-30 (Crawled : 22:00) - prnewswire.com
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
macular positive results diabetic
Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
Published: 2022-09-28 (Crawled : 23:00) - globenewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 0.22%
H: 0.33%
C: 0.33%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: -0.08%
H: 0.25%
C: -1.85%
dupixent treatment fda approved
Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis
Published: 2022-09-28 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 0.22%
H: 0.33%
C: 0.33%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: -0.08%
H: 0.25%
C: -1.85%
dupixent treatment fda approved
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
Published: 2022-09-16 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 0.74%
H: 0.91%
C: -0.74%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: 0.62%
H: 1.12%
C: 0.01%
NTLA | $21.17 -1.67% -1.75% 710K
|
Health Technology
|
| O: -3.76%
H: 0.36%
C: -0.44%
ntla-2001 treatment ongoing crispr therapy study
Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet
Published: 2022-09-15 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 0.74%
H: 0.91%
C: -0.74%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: 0.62%
H: 1.12%
C: 0.01%
dupixent children lancet dermatitis positive
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 13:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 12:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | $143.8 -1.55% -1.58% 400K
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM
Published: 2022-09-12 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -0.78%
H: 0.58%
C: 0.58%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: 0.0%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: -0.55%
H: 0.43%
C: -1.33%
libtayo positive cell carcinoma
Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors
Published: 2022-09-12 (Crawled : 07:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -0.78%
H: 0.58%
C: 0.58%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: 0.0%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: -0.55%
H: 0.43%
C: -1.33%
libtayo melanoma response
Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors
Published: 2022-09-10 (Crawled : 08:20) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis
Published: 2022-09-08 (Crawled : 18:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: 15.18%
H: 4.65%
C: 3.18%
dupixent
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis
Published: 2022-09-08 (Crawled : 16:00) - globenewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: 15.18%
H: 4.65%
C: 3.18%
dupixent
Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals
Published: 2022-09-08 (Crawled : 13:20) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: 15.18%
H: 4.65%
C: 3.18%
trials global
Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Published: 2022-09-05 (Crawled : 12:00) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
dupixent children
Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
Published: 2022-09-05 (Crawled : 06:00) - globenewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
| Email alert
Add to watchlist
dupixent children
ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers
Published: 2022-09-04 (Crawled : 00:00) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
| Email alert
Add to watchlist
libtayo potential
Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Published: 2022-08-03 (Crawled : 11:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: 4.36%
H: 3.91%
C: 1.46%
libtayo antibody cancer prostate cancer pd-1 inhibitor
Regeneron Reports Second Quarter 2022 Financial and Operating Results
Published: 2022-08-03 (Crawled : 11:00) - prnewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 310
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
|
| O: 4.36%
H: 3.91%
C: 1.46%
results
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.